Use: Labeled indications
- INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or…
Full indications and usage US FDA label
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. AZACTAM is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *.
Lower Respiratory Tract Infections, including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species.
Skin and Skin-Structure Infections, including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *.
Gynecologic Infections, including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. AZACTAM is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces.
AZACTAM is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. ------------------------------- * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Concurrent Therapy Concurrent initial therapy with other antimicrobial agents and AZACTAM is recommended before the causative organism(s) is known in seriously ill patients who are also at risk of having an infection due to Gram-positive aerobic pathogens.
If anaerobic organisms are also suspected as etiologic agents, therapy should be initiated using an anti-anaerobic agent concurrently with AZACTAM (see DOSAGE AND ADMINISTRATION). Certain antibiotics (eg, cefoxitin, imipenem) may induce high levels of beta-lactamase in vitro in some Gram-negative aerobes such as Enterobacter and Pseudomonas species, resulting in antagonism to many beta-lactam antibiotics including aztreonam.
These in vitro findings suggest that such beta-lactamase-inducing antibiotics not be used concurrently with aztreonam. Following identification and susceptibility testing of the causative organism(s), appropriate antibiotic therapy should be continued.
Contraindications
- Known hypersensitivity to aztreonam or any component
Contraindications (US label) US FDA label
CONTRAINDICATIONS This preparation is contraindicated in patients with known hypersensitivity to aztreonam or any other component in the formulation.
Dosing: Adult
- Urinary tract infections: 500 mg or 1 g IV or IM every 8 or 12 hours
- Moderately severe systemic infections: 1 or 2 g every 8 or 12 hours
- Severe or life-threatening infections, P. aeruginosa: 2 g every 6 or 8 hours
- Maximum: 8 g/day
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Dosage in Adult Patients AZACTAM may be administered intravenously or by intramuscular injection. Dosage and route of administration should be determined by susceptibility of the causative organisms, severity and site of infection, and the condition of the patient. Table 2: AZACTAM Dosage Guidelines for Adults* * Maximum recommended dose is 8 g per day.
Type of Infection Dose Frequency (hours) Urinary tract infections 500 mg or 1 g 8 or 12 Moderately severe systemic infections 1 g or 2 g 8 or 12 Severe systemic or life-threatening infections 2 g 6 or 8 Because of the serious nature of infections due to Pseudomonas aeruginosa, dosage of 2 g every six or eight hours is recommended, at least upon initiation of therapy, in systemic infections caused by this organism. The intravenous route is recommended for patients requiring single doses greater than 1 g or those with bacterial septicemia, localized parenchymal abscess (eg, intra-abdominal abscess), peritonitis, or other severe systemic or life-threatening infections.
The duration of therapy depends on the severity of infection. Generally, AZACTAM should be continued for at least 48 hours after the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. Persistent infections may require treatment for several weeks. Doses smaller than those indicated should not be used.
Renal Impairment in Adult Patients Prolonged serum levels of aztreonam may occur in patients with transient or persistent renal insufficiency. Therefore, the dosage of AZACTAM should be halved in patients with estimated creatinine clearances between 10 and 30 mL/min/1.73 m² after an initial loading dose of 1g or 2 g. When only the serum creatinine concentration is available, the following formula (based on sex, weight, and age of the patient) may be used to approximate the creatinine clearance (ClCr).
The serum creatinine should represent a steady state of renal function. In patients with severe renal failure (creatinine clearance less than 10 mL/min/1.73 m²), such as those supported by hemodialysis, the usual dose of 500 mg, 1 g, or 2 g should be given initially. The maintenance dose should be one-fourth of the usual initial dose given at the usual fixed interval of 6, 8, or 12 hours.
For serious or life-threatening infections, in addition to the maintenance doses, one-eighth of the initial dose should be given after each hemodialysis session. clcr-equation Dosage in the Elderly Renal status is a major determinant of dosage in the elderly; these patients in particular may have diminished renal function. Serum creatinine may not be an accurate determinant of renal status.
Therefore, as with all antibiotics eliminated by the kidneys, estimates of creatinine clearance should be obtained and appropriate dosage modifications made if necessary. Dosage in Pediatric Patients AZACTAM should be administered intravenously to pediatric patients with normal renal function. There are insufficient data regarding intramuscular administration to pediatric patients or dosing in pediatric patients with renal impairment.
(See PRECAUTIONS: Pediatric Use.) Table 3: AZACTAM Dosage Guidelines for Pediatric Patients* * Maximum recommended dose is 120 mg/kg/day. Type of Infection Dose Frequency (hours) Mild to moderate infections 30 mg/kg 8 Moderate to severe infections 30 mg/kg 6 or 8
Dosing: Altered kidney function
Aztreonam is excreted in urine by both filtration and tubular secretion, and its half-life is prolonged in kidney impairment. The US label gives a usual 1 or 2 g loading dose, then half the usual dose at creatinine clearance (CrCl) 10–30 mL/min/1.73 m2 and one-quarter below 10, with an extra one-eighth of the initial dose after each hemodialysis in serious infections.
Kidney function measure: Label uses CrCl in mL/min/1.73 m2 (formula quoted); bands at 30 and 10. The mL/min/1.73 m2 unit is the label's own convention and is kept verbatim.
Show full dosing details
- CrCl ≥60 mL/min/1.73 m2
- No dose change (label).
- CrCl 30–59 mL/min/1.73 m2
- No dose change above CrCl 30. At CrCl 30: as the 10–30 row (initial 1 or 2 g, then half the usual dose) (label).
- CrCl 15–29 mL/min/1.73 m2
- CrCl 10–30: initial 1 or 2 g, then half the usual dose at the usual interval (label).
- CrCl <15 mL/min/1.73 m2 (not on dialysis)
- CrCl 10–14: initial 1 or 2 g, then half the usual dose. Below 10: usual initial dose (500 mg, 1 g or 2 g), then one-fourth of the initial dose at the usual 6-, 8- or 12-hour interval (label).
- Hemodialysis (intermittent)
- Usual initial dose (500 mg, 1 g or 2 g), then one-fourth of the initial dose at the usual 6-, 8- or 12-hour interval; for serious or life-threatening infections, also give one-eighth of the initial dose after each hemodialysis (label).
- Peritoneal dialysis
- No peritoneal dialysis dosing in label (aztreonam can be cleared by peritoneal dialysis, overdose section). IV aztreonam rapidly reaches therapeutic levels in peritoneal dialysis fluid, and intraperitoneal aztreonam rapidly produces therapeutic serum levels (label PK); the label gives no dose. For PD-associated peritonitis (ISPD 2022): intraperitoneal intermittent 2 g daily; continuous loading dose 500 mg/L, then 250 mg/L in each exchange. Specialist input.
- CRRT
- Not in label; the cited CRRT review (Li 2020) gives no regimen for this drug. Specialist input.
- Dialyzable? Yes: may be cleared by hemodialysis and peritoneal dialysis (label). Protein binding about 56%.
- Monitoring CrCl for dose (serum creatinine may overestimate kidney function in older adults; label); diarrhea (CDAD).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual pediatric dose (label).
- eGFR 30–59
- Insufficient data on dosing in children with kidney impairment (label). Specialist input.
- eGFR 15–29
- Insufficient data on dosing in children with kidney impairment (label). Specialist input.
- eGFR <15 (not on dialysis)
- Insufficient data on dosing in children with kidney impairment (label). Specialist input.
- Hemodialysis (intermittent)
- Insufficient data on dosing in children with kidney impairment (label). Specialist input.
- Peritoneal dialysis
- Insufficient data on dosing in children with kidney impairment (label). Specialist input.
- CRRT
- Insufficient data on dosing in children with kidney impairment (label). Specialist input.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Dosage and administration (renal excerpts) US FDA label
Renal Impairment in Adult Patients Prolonged serum levels of aztreonam may occur in patients with transient or persistent renal insufficiency.
Therefore, the dosage of AZACTAM should be halved in patients with estimated creatinine clearances between 10 and 30 mL/min/1.73 m 2 after an initial loading dose of 1g or 2 g.
When only the serum creatinine concentration is available, the following formula (based on sex, weight, and age of the patient) may be used to approximate the creatinine clearance (ClCr).
The serum creatinine should represent a steady state of renal function.
In patients with severe renal failure (creatinine clearance less than 10 mL/min/1.73 m 2 ), such as those supported by hemodialysis, the usual dose of 500 mg, 1 g, or 2 g should be given initially.
For serious or life-threatening infections, in addition to the maintenance doses, one-eighth of the initial dose should be given after each hemodialysis session. clcr-equation Dosage in the Elderly Renal status is a major determinant of dosage in the elderly; these patients in particular may have diminished renal function.
Serum creatinine may not be an accurate determinant of renal status.
Therefore, as with all antibiotics eliminated by the kidneys, estimates of creatinine clearance should be obtained and appropriate dosage modifications made if necessary.
Dosage in Pediatric Patients AZACTAM should be administered intravenously to pediatric patients with normal renal function.
There are insufficient data regarding intramuscular administration to pediatric patients or dosing in pediatric patients with renal impairment. (See PRECAUTIONS: Pediatric Use .) Table 3: AZACTAM Dosage Guidelines for Pediatric Patients* * Maximum recommended dose is 120 mg/kg/day.
Dosing: Pediatric
- Approved ages
- 9 months and older, IV (label).
- Usual dose
- Mild to moderate infections: 30 mg/kg every 8 hours; moderate to severe: 30 mg/kg every 6 or 8 hours (label).
- Maximum dose
- 120 mg/kg/day (label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
Pediatric Use The safety and effectiveness of intravenous AZACTAM have been established in the age groups 9 months to 16 years. Use of AZACTAM in these age groups is supported by evidence from adequate and well-controlled studies of AZACTAM in adults with additional efficacy, safety, and pharmacokinetic data from noncomparative clinical studies in pediatric patients.
Sufficient data are not available for pediatric patients under 9 months of age or for the following treatment indications/pathogens: septicemia and skin and skin-structure infections (where the skin infection is believed or known to be due to H. influenzae type b). In pediatric patients with cystic fibrosis, higher doses of AZACTAM may be warranted.
(See CLINICAL PHARMACOLOGY, DOSAGE AND ADMINISTRATION, and CLINICAL STUDIES.)
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use Clinical studies of AZACTAM did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
In elderly patients, the mean serum half-life of aztreonam increased and the renal clearance decreased, consistent with the age-related decrease in creatinine clearance. Since aztreonam is known to be substantially excreted by the kidney, the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
Because elderly patients are more likely to have decreased renal function, renal function should be monitored and dosage adjustments made accordingly (see DOSAGE AND ADMINISTRATION: Renal Impairment in Adult Patients and Dosage in the Elderly). AZACTAM contains no sodium.
Dosage forms
Philippines
- Powder for injection: 1 g
- Powder for solution for injection: 1 g
Registered products in the Philippines
8 products registered with the Food and Drug Administration (FDA) Philippines list Aztreonam as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products8
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AzmironAztreonam | 1 g Powder for Injection (IM/IV)20 mL-capacity clear glass vial with rubber stopper and aluminum flip-off seal (Box of 1's) | Rx | Maya Biotech Private LimitedIndia | Elixir Pharma Inc. | DRP-17494 | Jan 9, 2031 | |
AztramAztreonam | 1g Powder for Injection (IM/IV)USP Type I Glass Vial (Box of 1's) | Rx | Swiss Parenterals Ltd.India | Endure Medical, Inc. | DR-XY46734 | Sep 27, 2029 | |
AztremAztreonam | 1g Powder for Injection (IM/IV)20 mL Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Red Aluminum Flip- Off Seal Cap x 1's (Box of 1's) | Rx | Kwality Pharmaceuticals Ltd.India | Pharma Surrey International, Inc. | DRP-14588 | Oct 19, 2028 | |
AztreogetAztreonam | 1 g Powder for Solution for Injection (IM/IV)20 mL-capacity USP type I clear glass vial with rubber stopper and pink aluminum flip-off seal (Box of 1’s) | Rx | Venus Remedies Ltd.India | 2MG Incorporated | DRP-18139 | May 13, 2032 | |
BrixonamAztreonam | 1g Powder for Injection (IM/IV)20 mL Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Red Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Kwality Pharmaceuticals Ltd.India | Brixmed Pharma Care, Inc.Importer: Pharma-Surrey International, Inc. | DRP-14588-01 | Oct 19, 2028 | |
MonobacAztreonam | 1 g Powder for Injection (IM/IV)Type I clear glass vial x 20 mL with grey butyl rubber stopper, aluminum seal, and pink flip-off cap (Box of 1's) | Rx | Venus Remedies LimitedIndia | Biocare Lifesciences, Inc. | DRP-17465 | Jan 6, 2031 | |
OptreonAztreonam | 1 g Powder for Injection (IM/IV)20 mL Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Red Aluminum Flip-Off Seal Cap x 1’s (Box of 1’s) | Rx | Kwality Pharmaceuticals Ltd.India | Option One EnterpriseImporter: Pharma-Surrey International, Inc. | DRP-14588-03 | Oct 19, 2028 | |
SantronAztreonam | 1 g Powder for Injection (I.M./I.V.) | Rx | Zeiss Pharmaceutical Pvt. Ltd. | Philcare Pharma Inc.Importer: SRS Life Sciences Inc. | DRP-5143 | Jan 27, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS Both animal and human data suggest that AZACTAM (aztreonam for injection, USP) is rarely cross-reactive with other beta-lactam antibiotics and weakly immunogenic. Treatment with aztreonam can result in hypersensitivity reactions in patients with or without prior exposure. (See CONTRAINDICATIONS.) Careful inquiry should be made to determine whether the patient has any history of hypersensitivity reactions to any allergens.
While cross-reactivity of aztreonam with other beta-lactam antibiotics is rare, this drug should be administered with caution to any patient with a history of hypersensitivity to beta-lactams (eg, penicillins, cephalosporins, and/or carbapenems). Treatment with aztreonam can result in hypersensitivity reactions in patients with or without prior exposure to aztreonam.
If an allergic reaction to aztreonam occurs, discontinue the drug and institute supportive treatment as appropriate (eg, maintenance of ventilation, pressor amines, antihistamines, corticosteroids). Serious hypersensitivity reactions may require epinephrine and other emergency measures. (See ADVERSE REACTIONS.) Clostridium difficile –associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including AZACTAM, and may range in severity from mild diarrhea to fatal colitis.
Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. Rare cases of toxic epidermal necrolysis have been reported in association with aztreonam in patients undergoing bone marrow transplant with multiple risk factors including sepsis, radiation therapy, and other concomitantly administered drugs associated with toxic epidermal necrolysis.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Beta-lactamase-inducing antibiotics (for example cefoxitin, imipenem) | Avoid | In vitro antagonism with aztreonam in some gram-negative aerobes such as Enterobacter and Pseudomonas (label). | Do not use concurrently (label). |
| Probenecid, furosemide | Minor | Clinically insignificant rise in aztreonam serum levels (label). | No action needed. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Phlebitis or injection-site discomfort (about 2%)
- Rash, diarrhea, nausea
Serious
- Anaphylaxis
- Clostridioides difficile-associated diarrhea
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Local reactions such as phlebitis/thrombophlebitis following intravenous administration, and discomfort/swelling at the injection site following intramuscular administration occurred at rates of approximately 1.9% and 2.4%, respectively. Systemic reactions (considered to be related to therapy or of uncertain etiology) occurring at an incidence of 1% to 1.3% include diarrhea, nausea and/or vomiting, and rash.
Reactions occurring at an incidence of less than 1% are listed within each body system in order of decreasing severity: Hypersensitivity —anaphylaxis, angioedema, bronchospasm Hematologic —pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis Gastrointestinal —abdominal cramps; rare cases of C. difficile –associated diarrhea, including pseudomembranous colitis, or gastrointestinal bleeding have been reported. Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment.
(See WARNINGS.) Dermatologic —toxic epidermal necrolysis (see WARNINGS), purpura, erythema multiforme, exfoliative dermatitis, urticaria, petechiae, pruritus, diaphoresis Cardiovascular —hypotension, transient ECG changes (ventricular bigeminy and PVC), flushing Respiratory —wheezing, dyspnea, chest pain Hepatobiliary —hepatitis, jaundice Nervous System —seizure, confusion, encephalopathy, vertigo, paresthesia, insomnia, dizziness Musculoskeletal —muscular aches Special Senses —tinnitus, diplopia, mouth ulcer, altered taste, numb tongue, sneezing, nasal congestion, halitosis Other —vaginal candidiasis, vaginitis, breast tenderness Body as a Whole —weakness, headache, fever, malaise Pediatric Adverse Reactions Of the 612 pediatric patients who were treated with AZACTAM in clinical trials, less than 1% required discontinuation of therapy due to adverse events. The following systemic adverse events, regardless of drug relationship, occurred in at least 1% of treated patients in domestic clinical trials: rash (4.3%), diarrhea (1.4%), and fever (1.0%).
These adverse events were comparable to those observed in adult clinical trials. In 343 pediatric patients receiving intravenous therapy, the following local reactions were noted: pain (12%), erythema (2.9%), induration (0.9%), and phlebitis (2.1%). In the US patient population, pain occurred in 1.5% of patients, while each of the remaining 3 local reactions had an incidence of 0.5%.
The following laboratory adverse events, regardless of drug relationship, occurred in at least 1% of treated patients: increased eosinophils (6.3%), increased platelets (3.6%), neutropenia (3.2%), increased AST (3.8%), increased ALT (6.5%), and increased serum creatinine (5.8%). In US pediatric clinical trials, neutropenia (absolute neutrophil count less than 1000/mm 3) occurred in 11.3% of patients (8/71) younger than 2 years receiving 30 mg/kg every 6 hours.
AST and ALT elevations to greater than 3 times the upper limit of normal were noted in 15% to 20% of patients aged 2 years or above receiving 50 mg/kg every 6 hours. The increased frequency of these reported laboratory adverse events may be due to either increased severity of illness treated or higher doses of AZACTAM administered.
Adverse Laboratory Changes Adverse laboratory changes without regard to drug relationship that were reported during clinical trials were: Hepatic —elevations of AST (SGOT), ALT (SGPT), and alkaline phosphatase; signs or symptoms of hepatobiliary dysfunction occurred in less than 1% of recipients (see above). Hematologic —increases in prothrombin and partial thromboplastin times, positive Coombs’ test.
Renal —increases in serum creatinine.
Monitoring parameters
- CrCl for dose (serum creatinine may overestimate kidney function in older adults; label); diarrhea (CDAD). Kidney
- CrCl for dose
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy In pregnant women, aztreonam crosses the placenta and enters the fetal circulation. Developmental toxicity studies in pregnant rats and rabbits with daily doses of aztreonam up to 1800 and 1200 mg/kg, respectively, revealed no evidence of embryotoxicity or fetotoxicity or teratogenicity. These doses, based on body surface area, are 2.2- and 2.9-fold greater than the MRHD for adults of 8 g per day.
A peri/postnatal study in rats revealed no drug-induced changes in any maternal, fetal, or neonatal parameters. The highest dose used in this study, 1800 mg/kg/day, is 2.2 times the MRHD based on body surface area. There are no adequate and well-controlled studies of aztreonam on human pregnancy outcomes. Because animal reproduction studies are not always predictive of human response, aztreonam should be used during pregnancy only if clearly needed.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Aztreonam is excreted in human milk in concentrations that are less than 1% of concentrations determined in simultaneously obtained maternal serum; consideration should be given to temporary discontinuation of nursing and use of formula feedings.
Pharmacokinetics
Key PK parameters
| Half-life | About 1.7 hours |
|---|---|
| Half-life in kidney failure (ESKD) kidney | Prolonged in kidney impairment (label; no value given) |
| Volume of distribution | About 12.6 L |
| Protein binding | About 56% |
| Renal excretion kidney | Mainly urine, by tubular secretion and filtration about equally (label; % not given) |
| Dialyzability kidney | Yes (hemodialysis and peritoneal dialysis) |
The serum half-life of aztreonam averaged 1.7 hours (1.5-2.0) in subjects with normal renal function, independent of the dose and route of administration.
In healthy subjects, based on a 70 kg person, the serum clearance was 91 mL/min and renal clearance was 56 mL/min; the apparent mean volume of distribution at steady-state averaged 12.6 liters, approximately equivalent to extracellular fluid volume.
In elderly patients, the mean serum half-life of aztreonam increased and the renal clearance decreased, consistent with the age-related decrease in creatinine clearance.
In patients with impaired renal function, the serum half-life of aztreonam is prolonged.
(See DOSAGE AND ADMINISTRATION: Renal Impairment in Adult Patients .) The serum half-life of aztreonam is only slightly prolonged in patients with hepatic impairment since the liver is a minor pathway of excretion.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Single 30-minute intravenous infusions of 500 mg, 1 g, and 2 g doses of AZACTAM in healthy subjects produced aztreonam peak serum levels of 54 mcg/mL, 90 mcg/mL, and 204 mcg/mL, respectively, immediately after administration; at 8 hours, serum levels were 1 mcg/mL, 3 mcg/mL, and 6 mcg/mL, respectively (Figure 1). Single 3-minute intravenous injections of the same doses resulted in serum levels of 58 mcg/mL, 125 mcg/mL, and 242 mcg/mL at 5 minutes following completion of injection.
Serum concentrations of aztreonam in healthy subjects following completion of single intramuscular injections of 500 mg and 1 g doses are depicted in Figure 1; maximum serum concentrations occur at about 1 hour. After identical single intravenous or intramuscular doses of AZACTAM, the serum concentrations of aztreonam are comparable at 1 hour (1.5 hours from start of intravenous infusion) with similar slopes of serum concentrations thereafter.
FIGURE 1 The serum levels of aztreonam following single 500 mg or 1 g (intramuscular or intravenous) or 2 g (intravenous) doses of AZACTAM exceed the MIC 90 for Neisseria sp., Haemophilus influenzae, and most genera of the Enterobacteriaceae for 8 hours (for Enterobacter sp., the 8-hour serum levels exceed the MIC for 80% of strains). For Pseudomonas aeruginosa, a single 2 g intravenous dose produces serum levels that exceed the MIC 90 for approximately 4 to 6 hours.
All of the above doses of AZACTAM result in average urine levels of aztreonam that exceed the MIC 90 for the same pathogens for up to 12 hours. When aztreonam pharmacokinetics were assessed for adult and pediatric patients, they were found to be comparable (down to 9 months old). The serum half-life of aztreonam averaged 1.7 hours (1.5-2.0) in subjects with normal renal function, independent of the dose and route of administration.
In healthy subjects, based on a 70 kg person, the serum clearance was 91 mL/min and renal clearance was 56 mL/min; the apparent mean volume of distribution at steady-state averaged 12.6 liters, approximately equivalent to extracellular fluid volume. In elderly patients, the mean serum half-life of aztreonam increased and the renal clearance decreased, consistent with the age-related decrease in creatinine clearance.
The dosage of AZACTAM should be adjusted accordingly (see DOSAGE AND ADMINISTRATION: Renal Impairment in Adult Patients). In patients with impaired renal function, the serum half-life of aztreonam is prolonged. (See DOSAGE AND ADMINISTRATION: Renal Impairment in Adult Patients.) The serum half-life of aztreonam is only slightly prolonged in patients with hepatic impairment since the liver is a minor pathway of excretion.
Average urine concentrations of aztreonam were approximately 1100 mcg/mL, 3500 mcg/mL, and 6600 mcg/mL within the first 2 hours following single 500 mg, 1 g, and 2 g intravenous doses of AZACTAM (30-minute infusions), respectively. The range of average concentrations for aztreonam in the 8- to 12-hour urine specimens in these studies was 25 to 120 mcg/mL.
After intramuscular injection of single 500 mg and 1 g doses of AZACTAM, urinary levels were approximately 500 mcg/mL and 1200 mcg/mL, respectively, within the first 2 hours, declining to 180 mcg/mL and 470 mcg/mL in the 6- to 8-hour specimens. In healthy subjects, aztreonam is excreted in the urine about equally by active tubular secretion and glomerular filtration.
Approximately 60% to 70% of an intravenous or intramuscular dose was recovered in the urine by 8 hours. Urinary excretion of a single parenteral dose was essentially complete by 12 hours after injection. About 12% of a single intravenous radiolabeled dose was recovered in the feces. Unchanged aztreonam and the inactive beta-lactam ring hydrolysis product of aztreonam were present in feces and urine.
Intravenous or intramuscular administration of a single 500 mg or 1 g dose of AZACTAM every 8 hours for 7 days to healthy subjects produced no apparent accumulation of aztreonam or modification of its disposition characteristics; serum protein binding averaged 56% and was independent of dose. An average of about 6% of a 1 g intramuscular dose was excreted as a microbiologically inactive open beta-lactam ring hydrolysis product (serum half-life approximately 26 hours) of aztreonam in the 0‑ to 8-hour urine collection on the last day of multiple dosing.
Renal function was monitored in healthy subjects given aztreonam; standard tests (serum creatinine, creatinine clearance, BUN, urinalysis, and total urinary protein excretion) as well as special tests (excretion of N-acetyl-β-glucosaminidase, alanine aminopeptidase, and β 2 -microglobulin) were used. No abnormal results were obtained.
Aztreonam achieves measurable concentrations in the following body fluids and tissues: Table 1: Extravascular Concentrations of Aztreonam After a Single Parenteral Dose a a Tissue penetration is regarded as essential to therapeutic efficacy, but specific tissue levels have not been correlated with specific therapeutic effects. Fluid or Tissue Dose (g) Route Hours Post-injection Number of Patients Mean Concentration (mcg/mL or mcg/g) Fluids bile 1 IV 2 10 39 blister fluid 1 IV 1 6 20 bronchial secretion 2 IV 4 7 5 cerebrospinal fluid (inflamed meninges) 2 IV 0.9-4.3 16 3 pericardial fluid 2 IV 1 6 33 pleural fluid 2 IV 1.1-3.0 3 51 synovial fluid 2 IV 0.8-1.9 11 83 Tissues atrial appendage 2 IV 0.9-1.6 12 22 endometrium 2 IV 0.7-1.9 4 9 fallopian tube 2 IV 0.7-1.9 8 12 fat 2 IV 1.3-2.0 10 5 femur 2 IV 1.0-2.1 15 16 gallbladder 2 IV 0.8-1.3 4 23 kidney 2 IV 2.4-5.6 5 67 large intestine 2 IV 0.8-1.9 9 12 liver 2 IV 0.9-2.0 6 47 lung 2 IV 1.2-2.1 6 22 myometrium 2 IV 0.7-1.9 9 11 ovary 2 IV 0.7-1.9 7 13 prostate 1 IM 0.8-3.0 8 8 skeletal muscle 2 IV 0.3-0.7 6 16 skin 2 IV 0.0-1.0 8 25 sternum 2 IV 1 6 6 The concentration of aztreonam in saliva at 30 minutes after a single 1 g intravenous dose (9 patients) was 0.2 mcg/mL; in human milk at 2 hours after a single 1 g intravenous dose (6 patients), 0.2 mcg/mL, and at 6 hours after a single 1 g intramuscular dose (6 patients), 0.3 mcg/mL; in amniotic fluid at 6 to 8 hours after a single 1 g intravenous dose (5 patients), 2 mcg/mL.
The concentration of aztreonam in peritoneal fluid obtained 1 to 6 hours after multiple 2 g intravenous doses ranged between 12 mcg/mL and 90 mcg/mL in 7 of 8 patients studied. Aztreonam given intravenously rapidly reaches therapeutic concentrations in peritoneal dialysis fluid; conversely, aztreonam given intraperitoneally in dialysis fluid rapidly produces therapeutic serum levels.
Concomitant administration of probenecid or furosemide and aztreonam causes clinically insignificant increases in the serum levels of aztreonam. Single-dose intravenous pharmacokinetic studies have not shown any significant interaction between aztreonam and concomitantly administered gentamicin, nafcillin sodium, cephradine, clindamycin, or metronidazole.
No reports of disulfiram-like reactions with alcohol ingestion have been noted; this is not unexpected since aztreonam does not contain a methyl-tetrazole side chain. Microbiology Mechanism of Action Aztreonam is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Aztreonam has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.
Mechanism of Resistance Resistance to aztreonam is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability. Interaction with Other Antimicrobials Aztreonam and aminoglycosides have been shown to be synergistic in vitro against most strains of P. aeruginosa, many strains of Enterobacteriaceae, and other Gram-negative aerobic bacilli.
Aztreonam has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Aerobic Gram-negative microorganisms: Citrobacter species Enterobacter species Escherichia coli Haemophilus influenzae (including ampicillin-resistant and other penicillinase-producing strains) Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia species The following in vitro data are available, but their clinical significance is unknown.
At least 90% of the following microorganisms exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for aztreonam. However, the efficacy of aztreonam in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials.
Aerobic Gram-negative microorganisms: Aeromonas hydrophila Morganella morganii Neisseria gonorrhoeae (including penicillinase-producing strains) Pasteurella multocida Proteus vulgaris Providencia stuartii Providencia rettgeri Yersinia enterocolitica Aztreonam and aminoglycosides have been shown to be synergistic in vitro against most strains of P. aeruginosa, many strains of Enterobacteriaceae, and other Gram-negative aerobic bacilli. Alterations of the anaerobic intestinal flora by broad-spectrum antibiotics may decrease colonization resistance, thus permitting overgrowth of potential pathogens, eg, Candida and Clostridium species.
Aztreonam has little effect on the anaerobic intestinal microflora in in vitro studies. Clostridium difficile and its cytotoxin were not found in animal models following administration of aztreonam. (See ADVERSE REACTIONS: Gastrointestinal.) Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.
Serum concentrations of aztreonam in healthy subjects following completion of single intramuscular injections of 500 mg and 1 g doses
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Aztreonam 1 g Powder | ₱1,189.00–₱4,888.88Reference ₱1,244.00 | per unit | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Aztreonam |
| PNF listing | Inj.: 1 g powder for injectionRestrictions: Reserve antimicrobial (PNF) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. AZACTAM · E.R. Squibb & Sons, L.L.C. [US FDA-approved label, version 15, December 15, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- E.R. Squibb & Sons, L.L.C. (2025). AZACTAM (aztreonam for injection, USP) [Prescribing information; US FDA-approved label, NDA050580, set ID 9a105eaf-ee77-4016-beeb-d425a5565db2, version effective December 15, 2025]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2
- Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .